Academic Journal
Rheumatologists' expectations and perceptions of T-cell redirecting therapies: results from a cross-sectional survey.
| Τίτλος: | Rheumatologists' expectations and perceptions of T-cell redirecting therapies: results from a cross-sectional survey. |
|---|---|
| Συγγραφείς: | Meinecke A; Department of Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. meinecke.anna@mh-hannover.de.; PRACTIS Clinician Scientist Program, Dean's Office for Academic Career Development, Hannover Medical School, Hannover, Germany. meinecke.anna@mh-hannover.de.; Working Group Young Rheumatology, German Society for Rheumatology, Berlin, Germany. meinecke.anna@mh-hannover.de., Knitza J; Working Group Young Rheumatology, German Society for Rheumatology, Berlin, Germany.; Institute for Digital Medicine, Philipps University Marburg, Marburg, Germany., Witte T; Working Group Young Rheumatology, German Society for Rheumatology, Berlin, Germany.; Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Rademacher J; Working Group Young Rheumatology, German Society for Rheumatology, Berlin, Germany.; Department of Gastroenterology, Infectiology and Rheumatology (Including Nutrition Medicine), Charite Universitätsmedizin Berlin, Berlin, Germany., Müller F; Working Group Young Rheumatology, German Society for Rheumatology, Berlin, Germany.; Division of Rheumatology and Clinical Immunology, Department of Medicine 3, University Hospital Augsburg, Augsburg, Germany., Düsing C; Working Group Young Rheumatology, German Society for Rheumatology, Berlin, Germany.; Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany., Zeeck M; Working Group Young Rheumatology, German Society for Rheumatology, Berlin, Germany.; Rheuma Zentrum Lübeck, Lübeck, Germany., Grieshaber-Bouyer R; Working Group Young Rheumatology, German Society for Rheumatology, Berlin, Germany.; Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.; Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Hagen M; Working Group Young Rheumatology, German Society for Rheumatology, Berlin, Germany.; Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.; Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Haase I; Working Group Young Rheumatology, German Society for Rheumatology, Berlin, Germany.; Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Holzer MT; Working Group Young Rheumatology, German Society for Rheumatology, Berlin, Germany. m.holzer@uke.de.; Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. m.holzer@uke.de. |
| Συλλογικό Έργο: | Working Group Young Rheumatologists of the German society for Rheumatology and Immunology |
| Πηγή: | Rheumatology international [Rheumatol Int] 2026 Sep 26; Vol. 46 (10). Date of Electronic Publication: 2026 Sep 26. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Springer International Country of Publication: Germany NLM ID: 8206885 Publication Model: Electronic Cited Medium: Internet ISSN: 1437-160X (Electronic) Linking ISSN: 01728172 NLM ISO Abbreviation: Rheumatol Int Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Berlin ; New York, NY] : Springer International, c1981- |
| Ιατρικοί όροι (MeSH): | Rheumatologists*/psychology , T-Lymphocytes*/immunology , Autoimmune Diseases*/therapy , Health Knowledge, Attitudes, Practice* , Attitude of Health Personnel* , Immunotherapy, Adoptive*, Humans ; Cross-Sectional Studies ; Adult ; Female ; Male ; Middle Aged ; Germany ; Prospective Studies ; Surveys and Questionnaires |
| Περίληψη: | T-cell redirecting therapies (TCRTs), including Chimeric antigen receptor (CAR)-T cells and T-cell engagers (TCEs), are emerging as transformative treatments for autoimmune diseases. However, clinical application is currently restricted to specialized centers, leaving most clinicians with limited first-hand experience. We aimed to assess the knowledge, perception, and barriers regarding TCRTs among German rheumatologists. A prospective, web-based survey was distributed to German rheumatologists via congresses and digital channels from September 2024 through January 2025. Drafting the design and reporting of the survey results was performed regarding international recommendations as the "checklist for reporting results of internet e-surveys" (CHERRIES). Statistical analysis was conducted with SPSS. Of 98 participants (median age 43 years) the majority was based at university hospitals (46.3%) and 94.8% were willing to refer patients to specialized centers. However, respondents considered only 5% of their patients suitable for TCRT, primarily those with severe, refractory connective tissue diseases. The main barriers cited were high costs (82%), limited clinical experience (65.5%) and applicability in only a limited number of patients (35.4%). Knowledge of side effects (e.g., cytokine release syndrome, infections, hypogammaglobulinemia) and contraindications (e.g. heart failure, chronic infections) was generally accurate. Yet, the self-appraisal of existing knowledge on TCRT was only seen as medium by the questioned rheumatologists (median of 4.86, on a 0 to 10 scale with 10 is best knowledge). Participating German rheumatologists demonstrated a high willingness to refer patients for TCRTs and appeared to possess good safety knowledge. However, the therapy is currently viewed as a niche option for highly active, refractory cases, with costs and limited data serving as primary barriers to broader implementation. (© 2026. The Author(s).) |
| Competing Interests: | Declarations. Conflict of interest: The authors declare no competing interests relevant to the study. Ethical approval: A formal enquiry was submitted to the ethics committee of the Philipps University Marburg, Germany (24–224 ANZ). Due to the anonymous and non-interventional nature of the study, it was deemed as exempted from IRB review. Participation was voluntary. This manuscript does not contain human or animal studies. Consent for publication: With participation, rheumatologists gave consent for publication of the anonymous survey results. |
| References: | JAMA Netw Open. 2025 Feb 03;8(2):e2461683. (PMID: 39998830) N Engl J Med. 2017 Mar 2;376(9):836-847. (PMID: 28249141) Clin Cancer Res. 2025 Dec 1;31(23):5027-5036. (PMID: 40938927) J Hepatol. 2026 Apr;84(4):829-836. (PMID: 41371348) N Engl J Med. 2025 Feb 6;392(6):584-598. (PMID: 39908433) Nat Med. 2024 Apr;30(4):984-989. (PMID: 38266761) N Engl J Med. 2024 Feb 22;390(8):687-700. (PMID: 38381673) J Korean Med Sci. 2023 Dec 11;38(48):e403. (PMID: 38084027) Rheumatology (Oxford). 2025 Sep 1;64(9):5101-5107. (PMID: 40268741) Am J Hematol. 2021 Sep 1;96(9):1101-1111. (PMID: 34057232) Eur J Cancer. 2024 Jul;205:114075. (PMID: 38733717) Med. 2024 Jun 14;5(6):550-558.e2. (PMID: 38554710) Mol Ther Methods Clin Dev. 2018 Dec 31;12:145-156. (PMID: 30666307) Ann Rheum Dis. 2026 May;85(5):958-961. (PMID: 41271520) Rheumatology (Oxford). 2022 May 5;61(5):1760-1768. (PMID: 35355064) N Engl J Med. 2024 Sep 5;391(9):864-866. (PMID: 39231352) N Engl J Med. 2018 Jul 5;379(1):64-73. (PMID: 29972754) Transplant Cell Ther. 2022 Jul;28(7):404.e1-404.e6. (PMID: 35354101) Cell Rep Med. 2024 Jul 16;5(7):101615. (PMID: 38897205) Am J Clin Oncol. 2019 Oct;42(10):789-796. (PMID: 31478934) Rheumatology (Oxford). 2024 Nov 1;63(11):2938-2947. (PMID: 38321569) Front Oncol. 2022 Nov 09;12:924208. (PMID: 36439485) Leukemia. 2003 May;17(5):900-9. (PMID: 12750704) J Med Internet Res. 2004 Sep 29;6(3):e34. (PMID: 15471760) JAMA Netw Open. 2024 Oct 1;7(10):e2437157. (PMID: 39374023) Mol Ther. 2024 Sep 4;32(9):2856-2891. (PMID: 39095991) J Clin Oncol. 2021 Dec 10;39(35):3978-3992. (PMID: 34724386) Front Immunol. 2026 Jan 30;17:1747777. (PMID: 41694371) Lancet. 2023 Nov 25;402(10416):2019-2033. (PMID: 38240831) Ann Rheum Dis. 2023 Aug;82(8):1117-1120. (PMID: 37147112) N Engl J Med. 2024 Sep 5;391(9):867-869. (PMID: 39231353) Nat Med. 2024 Jun;30(6):1593-1601. (PMID: 38671240) N Engl J Med. 2025 Oct 16;393(15):1544-1547. (PMID: 41092336) Front Immunol. 2025 Oct 22;16:1630569. (PMID: 41200159) N Engl J Med. 2025 Jul 24;393(4):349-361. (PMID: 40454646) Blood Cell Ther. 2023 Nov 25;6(4):145-150. (PMID: 38149027) Nat Rev Clin Oncol. 2023 Jun;20(6):359-371. (PMID: 37055515) J Card Fail. 2025 Feb;31(2):415-455. (PMID: 39419165) Cancer Treat Rev. 2025 Sep;139:102991. (PMID: 40644745) Ann Rheum Dis. 2025 Mar;84(3):e4-e7. (PMID: 39893102) N Engl J Med. 2024 Jun 13;390(22):2047-2060. (PMID: 38865660) J Immunother Cancer. 2024 Feb 21;12(2):. (PMID: 38388168) |
| Contributed Indexing: | Keywords: Autoimmune diseases; Health, knowledge, attitudes, practice; Immunotherapy, adoptive; Professional practice; Surveys and questionnaires |
| Entry Date(s): | Date Created: 20260926 Date Completed: 20260926 Latest Revision: 20260929 |
| Update Code: | 20260929 |
| PubMed Central ID: | PMC13615921 |
| DOI: | 10.1007/s00296-026-06300-3 |
| PMID: | 42799770 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1437-160X |
|---|---|
| DOI: | 10.1007/s00296-026-06300-3 |